Immunologic function and virologic suppression among children with perinatally acquired HIV infection on highly active antiretroviral therapy

Medical Care

Volumn 43, Issue 9 SUPPL., 2005, Pages

  Rutstein, Richard M ^a   Gebo, Kelly A ^b   Flynn, Patricia M ^c   Fleishman, John A ^d   Sharp, Victoria L ^e   Siberry, George K ^b   Spector, Stephen A ^f  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antiretroviral therapy; Pediatric HIV infection; Virologic suppression

Indexed keywords

EID: 24944582455     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000175636.34524.b9     Document Type: Article

References (36)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. Canani RB, Spagnuolo MI, Cirillo P, et al. Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy. AIDS. 1999;13:1005-1006.
5. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190-197.
6. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
7. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
8. Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet. 1992;339:1249-1253.
9. The Working Group on Antiretroviral Therapy. Guidelines for the use of antiretroviral agents in pediatric HIV therapy. Available at: http://www.aidsinfonihgov/guidelines. Accessed June 20, 2003.
10. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med. 1997;336:1337-1342.
11. Mofenson LM, Korelitz J, Meyer WA III, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997;175:1029-1038.
12. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
13. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
14. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43.
15. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
16. Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15:1971-1978.
17. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
18. Centers for Disease Control and Prevention. 1994 Revised classification system for HIV infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43:1-19.
19. Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis. 2003;37:951-958.
20. Starr SE, Fletcher C, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999;341:1874-1881.
21. van Rossum AM, Geelen SP, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor - containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:1008-1016.
22. Thuret I, Michel G, Chambost H, et al. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency. AIDS. 1999;13:81-87.
23. Resino S, Bellon M, Gurbindo D, et al. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clin Infect Dis. 2003;37:1216-1225.
24. Caudill S, Goldman T, Marconi K. Evaluation of pediatric HIV care provided in Ryan White CARE Act Title IV women, infants, children, and youth clinics. AIDS Patient Care STDS. 2003;17:65-73.
25. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
26. Raboud JM, Rae S, Hogg RS, et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347-1350.
27. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
28. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679-1686.
29. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.
30. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immun Defic Syndr. 2001;27:251-259.
31. Fleishman JA, Gebo KA, Moore RD. Disparities in virologic suppression among patients with HIV infection. In: Abstracts of the Academy Health Annual Research Meeting; San Diego, CA; June 6-8, 2004.
32. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immun Defic Syndr. 2000;25:115-123.
33. Gebo KA, Fleishman JA, Rubin HR, et al. Outpatient utilization is associated with opportunistic illness (OI) prophylaxis in a multistate sample of HIV patients. In: Proceedings of the 5th International Conference on Scientific Basis of Health Services Research; Washington, DC; September 2003.
34. McNaghten AD, Hanson DL, Jones JL, et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999;13:1687-1695.
35. Gebo K, Fleishman J, Conviser R, et al. Racial and gender disparities in receipt of HAART persist in a multi-state sample of HIV patients in 2001. J Acquir Immun Defic Syndr. In press.
36. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.